Trametinib Slows Recurrent Low-Grade Serous Ovarian Carcinoma
Median progression-free survival significantly prolonged with trametinib versus one of five standard-of-care treatment options
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.